Curaleaf and Jupiter Research Obtain EU Certification for Medical Cannabis Inhalation Device

LOS ANGELES- Curaleaf International, in collaboration with Jupiter Research LLC, a subsidiary of TILT Holdings Inc., has secured European Union (EU) medical device certification for a handheld liquid inhalation device designed for precise medical cannabis administration. The device is now certified as a Class IIa medical device under EU Regulation 2017/745, meeting stringent European regulatory standards.

The device features a magnetic snap-in cartridge and a rechargeable power supply, engineered to provide consistent and controlled cannabinoid delivery. A comprehensive technical file and full EU Declaration of Conformity were assessed and approved by a recognized EU Notified Body, validating the device’s quality, safety, and clinical robustness.

With this certification, the device is positioned for commercialization across multiple global markets, including European countries, the United Kingdom, Canada, and regions across Australasia. Healthcare professionals in these regions will be able to recommend the device for medical cannabis administration once it becomes commercially available.

Boris Jordan, Chairman and CEO of Curaleaf, stated that achieving EU medical certification signifies that medical cannabis innovation is progressing into mainstream global healthcare. Tim Conder, CEO of TILT Holdings, emphasized that the partnership with Curaleaf International exemplifies how technology can revolutionize healthcare, setting a new benchmark for the industry.